Parkin antibody (C-Term)
Quick Overview for Parkin antibody (C-Term) (ABIN928012)
Target
See all Parkin (PARK2) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term
-
Cross-Reactivity
- Mouse (Murine)
-
Purification
- Purified
-
Immunogen
- Park2 antibody was raised in rabbit using the C terminal of Park2 as the immunogen
-
-
-
-
Application Notes
-
WB: 0.2-1 µg/mL
Optimal conditions should be determined by the investigator. -
Comment
-
Park2 Blocking Peptide, (ABIN936245), is also available for use as a blocking control in assays to test for specificity of this Park2 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- Lot specific
-
Buffer
- Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store at 4 °C, following reconstitution, aliquot and store at -20 °C.
-
-
- Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
-
Alternative Name
- Park2
-
Background
- Park2 functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5 and AIMP2. Park2 may play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Park2 limits the production of reactive oxygen species (ROS). Synonyms: Polyclonal Park2 antibody, Anti-Park2 antibody, Parkinson disease, autosomal recessive, juvenile 2, parkin antibody, MGC130518 antibody, PRKN antibody.
-
Pathways
- Autophagy, Ubiquitin Proteasome Pathway
Target
-